Hemas Pharmaceuticals (pvt) Ltd

Hemas Pharmaceuticals (Pvt) Ltd, established in 1948, is a leading importer and distributor of pharmaceutical products in Sri Lanka. As a member of the Hemas Group, one of the country's most respected conglomerates, Hemas Pharmaceuticals has over seven decades of experience in shaping Sri Lanka's healthcare industry through innovation and an extensive distribution network.

The company offers a comprehensive portfolio, including pharmaceutical, surgical, diagnostics, consumer health, and animal health products. With a market share exceeding 30%, Hemas Pharmaceuticals serves over 3,000 pharmacies and 7,000 healthcare practitioners across the island, demonstrating its significant role in the nation's pharmaceutical distribution.

Hemas Pharmaceuticals operates a robust distribution network with a presence in over 3,000 pharmacies and 7,000 healthcare practitioners across Sri Lanka. This extensive reach is supported by a world-class supply chain system, ensuring steady product availability and efficient logistics. The company collaborates with more than 50 distributors, enhancing its capacity to deliver pharmaceutical products nationwide.

As a primary wholesaler and distributor, Hemas Pharmaceuticals plays a pivotal role in Sri Lanka's pharmaceutical supply chain. The company imports and distributes a wide range of pharmaceutical products, surgical and diagnostic items, consumer health products, and animal health products. Its extensive distribution network and partnerships with over 50 multinational companies underscore its significant position in the market.

Hemas Pharmaceuticals imports finished pharmaceutical formulations from eight verified Indian suppliers, with USV Private Limited being the largest contributor, accounting for 56.1% of the total import value. This concentration indicates a strategic choice to maintain strong relationships with key suppliers, ensuring consistent product quality and availability. The company's diversified portfolio, with 185 unique formulations, suggests a balanced approach to sourcing, mitigating risks associated with single-source dependency.

Hemas Pharmaceuticals' supply chain demonstrates resilience through its diversified sourcing from multiple Indian suppliers, reducing reliance on any single source. The company's importation of 185 unique formulations indicates a broad product base, enhancing its ability to adapt to market changes. While specific details on backup suppliers and shipping routes are not publicly disclosed, Hemas' established partnerships and extensive distribution network suggest a well-structured and resilient supply chain.

Hemas Pharmaceuticals' sourcing strategy, characterized by strong relationships with key Indian suppliers and a diversified product portfolio, positions the company to maintain a competitive edge in Sri Lanka's pharmaceutical market. For Indian exporters, this approach presents opportunities to strengthen existing partnerships and explore new collaborations, particularly in therapeutic areas where Hemas has a significant market presence.

The National Medicines Regulatory Authority (NMRA) is the primary regulatory body overseeing pharmaceutical imports in Sri Lanka. Key legislation governing pharma imports includes the Medicines (Pricing Mechanism for Medicines) Regulations, which grant the NMRA authority to control medicine prices. Importers must register pharmaceutical products with the NMRA and obtain approval before distribution. As of February 2026, the NMRA has introduced new requirements for price submissions, particularly for import licenses expiring on or after 1st February 2026.

Importers must maintain active import licenses and renew them regularly. The NMRA requires that all pharmaceutical products imported into Sri Lanka be registered and approved before distribution. Importers are also required to submit import data in a specified format to the NMRA. Regarding Good Manufacturing Practice (GMP) certifications, the NMRA recognizes international standards such as EU GMP, WHO GMP, and PIC/S. Importers must ensure that their suppliers hold valid GMP certifications to comply with regulatory requirements. (nmra.gov.lk)

Imported pharmaceutical products must undergo batch testing to ensure quality and safety. Stability requirements are enforced to guarantee product efficacy throughout its shelf life. Labeling must be in English and Sinhala, providing clear information on usage, dosage, and storage. Serialization mandates are in place to enhance traceability and prevent counterfeit products from entering the market.

In February 2026, the NMRA introduced new requirements for price submissions, particularly affecting import licenses expiring on or after 1st February 2026. This policy change aims to enhance transparency and control over pharmaceutical pricing in Sri Lanka.

Hemas Pharmaceuticals focuses on importing products in therapeutic areas such as nutritional supplements, immunosuppressants, and advanced oncology. The significant import value in these categories indicates a strategic alignment with market demand and the company's expertise. The emphasis on nutritional supplements (59.9%) and immunosuppressants (20.9%) suggests a commitment to addressing prevalent health concerns in Sri Lanka.

Hemas Pharmaceuticals' sourcing strategy emphasizes importing finished pharmaceutical formulations from reputable suppliers, primarily from India. The company's diversified product portfolio, with 185 unique formulations, reflects a comprehensive approach to meeting the diverse healthcare needs of the Sri Lankan market.

Hemas Pharmaceuticals serves a broad segment of the Sri Lankan market, including retail pharmacies, hospitals, government tenders, and wholesale distribution. Its extensive distribution network and diverse product portfolio enable the company to cater to various healthcare providers and consumers across the country.

There is a realistic opportunity for new Indian suppliers to collaborate with Hemas Pharmaceuticals, particularly in therapeutic areas where the company has a significant market presence. Identifying gaps in Hemas' current sourcing, such as emerging therapeutic categories or innovative formulations, could present avenues for new partnerships.

Indian exporters seeking to supply Hemas Pharmaceuticals must ensure their products are registered with the NMRA and comply with Sri Lankan import regulations. Suppliers must hold valid GMP certifications recognized by the NMRA, such as EU GMP, WHO GMP, or PIC/S. Adherence to quality standards, including batch testing, stability requirements, and labeling mandates, is essential.

Indian exporters should initiate contact with Hemas Pharmaceuticals by presenting their product portfolios and demonstrating compliance with NMRA regulations. Participating in tenders and engaging in discussions about regulatory filing strategies can facilitate collaboration. Understanding the regulatory framework and aligning with Hemas' product strategy will enhance the potential for a successful partnership.